Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

19.04 +0.67 (+3.65%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	971,479
Open	19.13
Bid (Size)	16.25 (2,000)
Ask (Size)	20.25 (200)
Prev. Close	18.37
Today's Range	17.63 - 19.41
52wk Range	7.800 - 20.25
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? ↗

Today 12:41 EDT

This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains.

Via The Motley Fool

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Today 7:30 EDT

From Bicara Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	+16.2%	+16.2%
1 Month	+13.5%	+13.5%
3 Month	+15.3%	+15.3%
6 Month	+37.3%	+37.3%
1 Year	+46.1%	+46.1%

More News

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. ↗

March 26, 2026

Via The Motley Fool

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

March 23, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

March 04, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 26, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

February 24, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

February 24, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics to Participate in Upcoming Investor Conferences

February 23, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

February 19, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 05, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

January 12, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

December 15, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

December 06, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025

December 01, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

November 20, 2025

Via Investor Brand Network

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 10, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

November 20, 2025

From BioMedWire

Via GlobeNewswire

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

October 27, 2025

Via Investor Brand Network

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

October 27, 2025

Via FinancialNewsMedia

These stocks that are showing activity before the opening bell on Monday. ↗

October 13, 2025

Via Chartmill

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

October 13, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

4 Biotech Stocks Seeing Explosive Momentum Gains ↗

October 07, 2025

Via Benzinga

Bicara Therapeutics to Participate in Upcoming Investor Conferences

August 27, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Bicara Therapeutics Inc. - Common Stock publicly traded?

Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Bicara Therapeutics Inc. - Common Stock trade on?

Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?

The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market

What is the current price of Bicara Therapeutics Inc. - Common Stock?

The current price of Bicara Therapeutics Inc. - Common Stock is 19.04

When was Bicara Therapeutics Inc. - Common Stock last traded?

The last trade of Bicara Therapeutics Inc. - Common Stock was at 03/30/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.